Trevena, Inc.
Trevena, Inc. is a biopharmaceutical company based in the United States that focuses on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders. The company is known for its innovative approach to drug discovery, particularly in the area of G protein-coupled receptors (GPCRs).
History[edit | edit source]
Trevena, Inc. was founded in 2007 by a team of scientists and entrepreneurs with a vision to leverage cutting-edge research in GPCR biology to develop new therapies. The company was initially supported by venture capital funding and has since grown to become a publicly traded entity on the NASDAQ stock exchange under the ticker symbol TRVN.
Research and Development[edit | edit source]
Trevena's research and development efforts are centered around the modulation of GPCRs, which are a large family of cell surface receptors that play a crucial role in many physiological processes. The company employs a proprietary platform to design biased ligands, which selectively activate specific signaling pathways associated with GPCRs, potentially leading to improved therapeutic outcomes with fewer side effects.
Key Products[edit | edit source]
One of Trevena's most notable products is oliceridine, a novel opioid analgesic designed to provide effective pain relief with a reduced risk of adverse effects commonly associated with traditional opioids, such as respiratory depression and constipation. Oliceridine has been approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in adults.
Pipeline[edit | edit source]
Trevena continues to advance its pipeline of drug candidates targeting various CNS disorders. The company's research is focused on developing treatments for conditions such as migraine, depression, and Parkinson's disease.
Corporate Structure[edit | edit source]
Trevena is headquartered in Chesterbrook, Pennsylvania, and operates with a team of experienced professionals in the fields of drug discovery, clinical development, and regulatory affairs. The company collaborates with academic institutions and other biopharmaceutical companies to enhance its research capabilities and accelerate the development of its drug candidates.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
